Trial of personalised care after treatment-Prostate cancer: A randomised feasibility trial of a nurse-led psycho-educational intervention
| Autor: | Marian Andrei Stanciu, Seow Tien Yeo, Matt Makin, Clare Wilkinson, Zoe Hoare, Jenna Bulger, Richard D Neal, Eila Watson, Julia Hiscock, Rhiannon Tudor Edwards, Richard Evans, Caroline Morris |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Male
medicine.medical_specialty Cost-Benefit Analysis 03 medical and health sciences Nurse led Prostate cancer 0302 clinical medicine Cancer Survivors Patient Education as Topic Intervention (counseling) Surveys and Questionnaires medicine Humans Attrition Precision Medicine Adverse effect Aged Aged 80 and over business.industry Prostatic Neoplasms Middle Aged medicine.disease Psychotherapy Treatment Outcome Oncology Sample size determination Patient Satisfaction 030220 oncology & carcinogenesis Needs assessment Physical therapy Feasibility Studies Quality-Adjusted Life Years business Delivery of Health Care After treatment |
| Zdroj: | European journal of cancer care. 28(2) |
| ISSN: | 1365-2354 |
| Popis: | Objective The present parallel randomised control trial evaluated the feasibility of a nurse-led psycho-educational intervention aimed at improving the self-management of prostate cancer survivors. Methods We identified 305 eligible patients from a district general hospital, diagnosed 9-48 months previously, who completed radical treatment, or were monitored clinically (ineligible for treatment). Ninety-five patients were recruited by blinded selection and randomised to Intervention (N = 48) and Control (N = 47) groups. Participant allocation was revealed to patients and researchers after recruitment was completed. For 36 weeks, participants received augmented usual care (Control) or augmented usual care and additional nurse support (Intervention) provided in two community hospitals and a university clinic, or by telephone. Results Data from 91 participants (Intervention, N = 45; Control, N = 46) were analysed. All feasibility metrics met predefined targets: recruitment rate (31.15%; 95% CI: 25.95%-36.35%), attrition rate (9.47%; 95% CI: 3.58%-15.36%) and outcome measures completion rates (77%-92%). Forty-five patients received the intervention, with no adverse events. The Extended Prostate Cancer Index Composite can inform the minimum sample size for a future effectiveness trial. The net intervention cost was £317 per patient. Conclusions The results supported the feasibility and acceptability of the intervention, suggesting that it should be evaluated in a fully powered trial to assess its effectiveness and cost-effectiveness. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|